Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

GSK plc GSK has announced the approval of the European Commission (EC) for the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy, in adults aged 50-59 years. The vaccine has ...

The safety and immunogenicity of Arexvy in adults aged 18 to 49 years at increased risk of RSV disease (n=395) was compared with adults aged 60 and older (n=417) in a phase 3b open-label trial ...

The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

London: GSK plc has announced that the US Food and Drug Administration (FDA) has accepted for review an application to extend ...

Winter is here, and with it come higher rates of respiratory illnesses. If you've been struck down recently with a sore ...

GSK is taking to the airwaves to get the message out about respiratory syncytial virus (RSV), presenting a TV special about how the pathogen has affected athletes in the upcoming National Senior Games ...

And AREXVY was 94.6% effective in preventing lung and lower airway infection from RSV in people aged 60 years and older with asthma, diabetes, chronic obstructive pulmonary disease, chronic heart ...

GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a Phase 3 trial. Read more here.

All three RSV vaccines -- GSK's Arexvy, Pfizer's Abrysvo, and Moderna's mRESVIA -- are FDA-approved for all adults age 60 and up (and one RSV vaccine, Pfizer's Abrysvo, ...